Table 5.
Response to first-line chemotherapy and survival in patients with CD20-negative diffuse large B-cell lymphoma and CD20-positive diffuse large B-cell lymphoma
| CD20-negative DLBCL(n = 21) | CD20-positive DLBCL (n = 63) | P | |
|---|---|---|---|
|
Response |
|
|
|
| Assessable, n |
21 |
63 |
|
| CR |
9 (42.9%) |
52(82.5%) |
0.001 |
| No CR |
12(57.1%) |
11(17.5%) |
|
|
Survival |
|
|
|
| 3-years PFS |
30.5% |
52% |
0.008 |
| Median PFS, months (range) |
6(1-117) |
39(2-121) |
|
| 3-years OS |
35% |
74.1 % |
0.008 |
| Median OS, months (range) | 23(3-117) | Not reached(2-121) |
DLBCL, diffuse large B-cell lymphoma; CR, complete remission; PFS, progression-free survival; OS, overall survival.